Paul Sarcia, MD
Cardiovascular Disease · Robbinsdale, MNNPI 1194915934
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $5,000 of the $7,926 with a category attached, or 63.1%. Canon Medical Informatics, Inc. accounts for 63.1% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2024 at $5,016 and has fallen 65.5% since, to $1,728 in 2025.
Across 27 payments — averaging $293.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Canon Medical Informatics, Inc.$5K
- Abbott$2K
- Philips North America LLC$838
- Edwards Lifesciences$185
- Heartflow, Inc.$166
- Boston Scientific$95
What the payments were for
- Speaking & faculty fees$5,00063%
- Grants$951%
- Travel & lodging$2,20728%
- Food & beverage$6248%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Canon Medical Informatics, Inc. | 2 | $5,000 |
| Abbott | 14 | $1,642 |
| Philips North America LLC | 4 | $838 |
| Edwards Lifesciences | 4 | $185 |
| Heartflow, Inc. | 2 | $166 |
| Boston Scientific | 1 | $95 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vitrea AV TAVR$4,999
- TRICLIP$1,437
- IGT Devices Und$758
How this compares
$7,926 in reported general payments places this provider in the 70th percentile of 451 cardiovascular disease providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 193 | $193,628 |
| EntrestoSacubitril/Valsartan | 62 | $85,879 |
| JardianceEmpagliflozin | 42 | $45,871 |
| Repatha SureclickEvolocumab | 42 | $41,765 |
| XareltoRivaroxaban | 22 | $28,045 |
| Metoprolol Succinate | 269 | $4,665 |
| Icosapent Ethyl | 12 | $3,908 |
| Ranolazine ErRanolazine | 17 | $1,751 |
| Atorvastatin Calcium | 108 | $1,540 |
| Losartan Potassium | 106 | $1,425 |
| Spironolactone | 107 | $1,126 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 56 | $1,119 |
| Flecainide Acetate | 31 | $1,106 |
| Ezetimibe | 52 | $1,074 |
| Rosuvastatin Calcium | 83 | $1,000 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Robbinsdale
- Jeffrey ChambersMinneapolis$3.2M
- Srijoy MahapatraRochester$1.2M
- Markus MeyerMinneapolis$786K
- Robert SchwartzMinneapolis$502K
- Robert VantasselMinneapolis$493K
- Charanjit RihalRochester$478K
- Amir LermanRochester$465K
- Nedaa SkeikMinneapolis$453K
- Joao CavalcanteMinneapolis$384K
- Inderjit AnandMinneapolis$384K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.